Huge success for the teams of Hermen Overkleeft and Hans Aerts of our LED3 hub. The compound nizubaglustat that originated in their labs for treating Niemann-Pick disease and gangliosidoses advanced to phase 3 studies by Azafaros with €132M in series B funding. www.azafaros.com/news/azafaro...
Azafaros Secures € 132M in Oversubscribed Series B Financing to advance Phase 3 clinical programs of innovative therapies in lysosomal storage disorders
Financing round led by Jeito Capital and co-led by Forbion Growth, with participation from Seroba, Pictet Group and other existing investors
Proceeds to fund two Phase 3
www.azafaros.com
May 14, 2025 at 7:47 AM
Huge success for the teams of Hermen Overkleeft and Hans Aerts of our LED3 hub. The compound nizubaglustat that originated in their labs for treating Niemann-Pick disease and gangliosidoses advanced to phase 3 studies by Azafaros with €132M in series B funding. www.azafaros.com/news/azafaro...
His fundamental scientific work has laid the foundation for three start-up companies (AZAFAROS B.V., iProtics and AVIGI Therapeutics) that are driving these developments forward to the clinics in order to hopefully help patients in the future. (4/5)
June 26, 2026 at 10:37 AM
His fundamental scientific work has laid the foundation for three start-up companies (AZAFAROS B.V., iProtics and AVIGI Therapeutics) that are driving these developments forward to the clinics in order to hopefully help patients in the future. (4/5)
Dr. Caroline Hastings is hugely supportive of our community and she is the principal investigator for the first site in the United States to open for the Azafaros Phase 3 NAVIGATE study. If you have questions, email us at info@curegm1.org
#curegm1 #advocacy #raredisease #charity #give
#curegm1 #advocacy #raredisease #charity #give
November 22, 2025 at 5:03 PM
Dr. Caroline Hastings is hugely supportive of our community and she is the principal investigator for the first site in the United States to open for the Azafaros Phase 3 NAVIGATE study. If you have questions, email us at info@curegm1.org
#curegm1 #advocacy #raredisease #charity #give
#curegm1 #advocacy #raredisease #charity #give
3/5
📌 SERIES B:
‣ Azafaros B.V. 🇳🇱 aims to develop new therapeutic agents for treating rare metabolic disorders.
Money raised: €132M
‣TILT Biotherapeutics Ltd 🇫🇮 is working in oncology towards enabling T-cell therapies and immune checkpoint inhibitors with oncolytic viruses.
Money raised: €22,6M
📌 SERIES B:
‣ Azafaros B.V. 🇳🇱 aims to develop new therapeutic agents for treating rare metabolic disorders.
Money raised: €132M
‣TILT Biotherapeutics Ltd 🇫🇮 is working in oncology towards enabling T-cell therapies and immune checkpoint inhibitors with oncolytic viruses.
Money raised: €22,6M
May 17, 2025 at 6:23 AM
3/5
📌 SERIES B:
‣ Azafaros B.V. 🇳🇱 aims to develop new therapeutic agents for treating rare metabolic disorders.
Money raised: €132M
‣TILT Biotherapeutics Ltd 🇫🇮 is working in oncology towards enabling T-cell therapies and immune checkpoint inhibitors with oncolytic viruses.
Money raised: €22,6M
📌 SERIES B:
‣ Azafaros B.V. 🇳🇱 aims to develop new therapeutic agents for treating rare metabolic disorders.
Money raised: €132M
‣TILT Biotherapeutics Ltd 🇫🇮 is working in oncology towards enabling T-cell therapies and immune checkpoint inhibitors with oncolytic viruses.
Money raised: €22,6M
Great talk by Kyle Landskroner from Azafaros at #MedChemFrontiers24. He talked about nizubaglustat for treating lysosomal storage disorders - a clinical candidate that started in the labs of Hans Aerts, Richard van den Berg and Hermen Overkleeft @led3hub.bsky.social. pubs.acs.org/doi/10.1021/...
Identification of Potent and Selective Glucosylceramide Synthase Inhibitors from a Library of N-Alkylated Iminosugars
Glucosylceramide synthase (GCS) is an important target for clinical drug development for the treatment of lysosomal storage disorders and a promising target for combating type 2 diabetes. Iminosugars ...
pubs.acs.org
April 10, 2024 at 10:39 AM
Great talk by Kyle Landskroner from Azafaros at #MedChemFrontiers24. He talked about nizubaglustat for treating lysosomal storage disorders - a clinical candidate that started in the labs of Hans Aerts, Richard van den Berg and Hermen Overkleeft @led3hub.bsky.social. pubs.acs.org/doi/10.1021/...
De investeringen in techstartups lagen in mei duidelijk op een hoger niveau dan de maand ervoor én een jaar geleden.
Biotechbedrijf Azafaros scoorde 132 miljoen euro, en er was de 72 miljoen voor AI-platform Toloka, dat eerder onderdeel was van het Russische Yandex.
Biotechbedrijf Azafaros scoorde 132 miljoen euro, en er was de 72 miljoen voor AI-platform Toloka, dat eerder onderdeel was van het Russische Yandex.
Investeringen in startups duidelijk hoger in mei 2025
Startups en scaleups haalden in mei 2025 duidelijk meer geld op dan de maand ervoor én een jaar geleden. Ook de bedragen zijn groter.
mtsprout.nl
May 30, 2025 at 12:19 PM
De investeringen in techstartups lagen in mei duidelijk op een hoger niveau dan de maand ervoor én een jaar geleden.
Biotechbedrijf Azafaros scoorde 132 miljoen euro, en er was de 72 miljoen voor AI-platform Toloka, dat eerder onderdeel was van het Russische Yandex.
Biotechbedrijf Azafaros scoorde 132 miljoen euro, en er was de 72 miljoen voor AI-platform Toloka, dat eerder onderdeel was van het Russische Yandex.
Exciting new publication by Azafaros accepted to a peer-reviewed medical journal of the RAINBOW study. Topline results from the study announced in 2024 demonstrated that nizubaglustat was safe and well tolerated, with encouraging signs of efficacy.
https://tinyurl.com/4fmafuw5
#curegm1 #raredise…
https://tinyurl.com/4fmafuw5
#curegm1 #raredise…
June 8, 2026 at 8:16 PM
Exciting new publication by Azafaros accepted to a peer-reviewed medical journal of the RAINBOW study. Topline results from the study announced in 2024 demonstrated that nizubaglustat was safe and well tolerated, with encouraging signs of efficacy.
https://tinyurl.com/4fmafuw5
#curegm1 #raredise…
https://tinyurl.com/4fmafuw5
#curegm1 #raredise…
Join us for two important events!
1. TODAY, we will hear about the AZAFAROS B.V. Phase 3 trial. Mail info@curegm1.org to be added to the invite!
2. REGISTER NOW for our annual community conference! In-person registration ends 7/24 and virtual registration closes on 7/31. curegm1.org/conference
1. TODAY, we will hear about the AZAFAROS B.V. Phase 3 trial. Mail info@curegm1.org to be added to the invite!
2. REGISTER NOW for our annual community conference! In-person registration ends 7/24 and virtual registration closes on 7/31. curegm1.org/conference
July 14, 2025 at 3:15 PM
Join us for two important events!
1. TODAY, we will hear about the AZAFAROS B.V. Phase 3 trial. Mail info@curegm1.org to be added to the invite!
2. REGISTER NOW for our annual community conference! In-person registration ends 7/24 and virtual registration closes on 7/31. curegm1.org/conference
1. TODAY, we will hear about the AZAFAROS B.V. Phase 3 trial. Mail info@curegm1.org to be added to the invite!
2. REGISTER NOW for our annual community conference! In-person registration ends 7/24 and virtual registration closes on 7/31. curegm1.org/conference
Congratulations to the entire AZAFAROS B.V. team on the series B financing! We truly appreciate the dedication to rare diseases.
READ MORE: tinyurl.com/3jbtvwws
#curegm1 #raredisease #biotech #privateequity #hope #drugdevelopment #clinicaltrials #science
READ MORE: tinyurl.com/3jbtvwws
#curegm1 #raredisease #biotech #privateequity #hope #drugdevelopment #clinicaltrials #science
May 13, 2025 at 4:32 PM
Congratulations to the entire AZAFAROS B.V. team on the series B financing! We truly appreciate the dedication to rare diseases.
READ MORE: tinyurl.com/3jbtvwws
#curegm1 #raredisease #biotech #privateequity #hope #drugdevelopment #clinicaltrials #science
READ MORE: tinyurl.com/3jbtvwws
#curegm1 #raredisease #biotech #privateequity #hope #drugdevelopment #clinicaltrials #science
January 8, 2025 at 5:51 PM
NEWS: Azafaros is poised to take its oral lysosomal storage disorder drug into phase 3, thanks to a big second-round financing.
pharmaphorum.com/news/azafaro...
pharmaphorum.com/news/azafaro...
Azafaros bags €132m for rare neuro-metabolic disorder drugs
Azafaros is set to start phase 3 trials of its lead drug for a trio of rare lysosomal storage disorders, backed by €132m in new Series B financing
pharmaphorum.com
May 13, 2025 at 10:04 AM
NEWS: Azafaros is poised to take its oral lysosomal storage disorder drug into phase 3, thanks to a big second-round financing.
pharmaphorum.com/news/azafaro...
pharmaphorum.com/news/azafaro...
Feed: "Endpoints News"
By: Kyle LaHucik on Tuesday, May 13, 2025
By: Kyle LaHucik on Tuesday, May 13, 2025
Dutch biotech Azafaros gets $146M for Phase 3 trials in three metabolic disorders
Azafaros raises $146M Series B to advance nizubaglustat into Phase 3 trials for rare lysosomal storage disorders, with potential drug approval in 2028.
endpts.com
May 13, 2025 at 2:48 PM
Feed: "Endpoints News"
By: Kyle LaHucik on Tuesday, May 13, 2025
By: Kyle LaHucik on Tuesday, May 13, 2025
Bringing your drug candidates to patients is what many academic chemists dream about, but the road to this goal is long and bumpy. Now, Leiden small molecule nizubaglustat is ready for phase 3 clinical trials. This is thanks to a €132 million funding secured by the biotech spin-out Azafaros.
Leiden-developed drug candidate ready for final clinical trial phase
Bringing your drug candidates to patients is what many academic chemists dream about, but the road to this goal is long and bumpy. Now, Leiden small molecule nizubaglustat is ready for phase 3 clinica...
www.universiteitleiden.nl
June 5, 2025 at 2:29 PM
Bringing your drug candidates to patients is what many academic chemists dream about, but the road to this goal is long and bumpy. Now, Leiden small molecule nizubaglustat is ready for phase 3 clinical trials. This is thanks to a €132 million funding secured by the biotech spin-out Azafaros.
Azafaros gets $146m in a Series B to go into late-stage trials for rare lysosomal storage disorders.
endpts.com/dutch-biotec...
endpts.com/dutch-biotec...
Dutch biotech gets $146M for late-stage trials in three metabolic disorders
Azafaros raises $146M Series B to advance nizubaglustat into Phase 3 trials for rare lysosomal storage disorders, with potential drug approval in 2028.
endpts.com
May 13, 2025 at 11:55 AM
Azafaros gets $146m in a Series B to go into late-stage trials for rare lysosomal storage disorders.
endpts.com/dutch-biotec...
endpts.com/dutch-biotec...
Azafaros' secures €132 million for rare disease treatment
https://ioplus.nl/en/posts/azafaros-secures-132-million-for-rare-disease-treatment
https://ioplus.nl/en/posts/azafaros-secures-132-million-for-rare-disease-treatment
Azafaros' secures €132 million for rare disease treatment
Azafaros secures €132M to advance trials for rare neurological therapies, targeting lysosomal storage disorders with innovative treatments.
ioplus.nl
May 14, 2025 at 2:04 PM
Azafaros' secures €132 million for rare disease treatment
https://ioplus.nl/en/posts/azafaros-secures-132-million-for-rare-disease-treatment
https://ioplus.nl/en/posts/azafaros-secures-132-million-for-rare-disease-treatment
Azafaros haalt €132 miljoen op voor behandeling zeldzame ziekte
https://ioplus.nl/nl/posts/azafaros-haalt-132-miljoen-op-voor-behandeling-zeldzame-ziekte
https://ioplus.nl/nl/posts/azafaros-haalt-132-miljoen-op-voor-behandeling-zeldzame-ziekte
Azafaros haalt €132 miljoen op voor behandeling zeldzame ziekte
Azafaros ontwikkelt proeven voor zeldzame neurologische therapieën, gericht op lysosomale opslagstoornissen met innovatieve behandelingen.
ioplus.nl
May 14, 2025 at 2:05 PM
Azafaros haalt €132 miljoen op voor behandeling zeldzame ziekte
https://ioplus.nl/nl/posts/azafaros-haalt-132-miljoen-op-voor-behandeling-zeldzame-ziekte
https://ioplus.nl/nl/posts/azafaros-haalt-132-miljoen-op-voor-behandeling-zeldzame-ziekte
Thoughts on this? >> Azafaros Announces Initiation of two Global Phase 3 studies
with Nizubaglustat in Niemann-Pick disease Type C (NPC) and GM1/GM2
gangliosidoses, respectively >> Comment below! #healthtech #AI #mhealth #IoT #industry40
with Nizubaglustat in Niemann-Pick disease Type C (NPC) and GM1/GM2
gangliosidoses, respectively >> Comment below! #healthtech #AI #mhealth #IoT #industry40
Azafaros Announces Initiation of two Global Phase 3 studies
with Nizubaglustat in Niemann-Pick disease Type C (NPC) and GM1/GM2
gangliosidoses, respectively
First patient dosed in global pivotal clinical trial program for late infantile/juvenile onset NPC and GM1/GM2 gangliosidoses. Both studies are part of Azafaros’ mission to develop treatments for the unmet need of patients with rare lysosomal storage disorders The news follows the company’s recent successful €132M Series B financing, aimed at supporting the rapid development …
dlvr.it
July 28, 2025 at 6:12 AM
Thoughts on this? >> Azafaros Announces Initiation of two Global Phase 3 studies
with Nizubaglustat in Niemann-Pick disease Type C (NPC) and GM1/GM2
gangliosidoses, respectively >> Comment below! #healthtech #AI #mhealth #IoT #industry40
with Nizubaglustat in Niemann-Pick disease Type C (NPC) and GM1/GM2
gangliosidoses, respectively >> Comment below! #healthtech #AI #mhealth #IoT #industry40
Thoughts on this? >> Azafaros to Present at BIO International Convention 2025
Following Successful €132M Series B Financing >> Comment below! #mhealth #AI #healthtech #IoT #industry40
Following Successful €132M Series B Financing >> Comment below! #mhealth #AI #healthtech #IoT #industry40
Azafaros to Present at BIO International Convention 2025
Following Successful €132M Series B Financing
LEIDEN, Netherlands–(BUSINESS WIRE)–#Adults–Azafaros, a clinical-stage biotechnology company developing novel therapies for rare lysosomal storage disorders (LSDs), today announced that it will present at the 2025 BIO International Convention taking place in Boston, USA, from 16-19 June. The company’s presentation is scheduled for Monday, June 16 at 16:45 ET in Room 153B. The presentation will highlight …
dlvr.it
June 9, 2025 at 5:45 AM
Thoughts on this? >> Azafaros to Present at BIO International Convention 2025
Following Successful €132M Series B Financing >> Comment below! #mhealth #AI #healthtech #IoT #industry40
Following Successful €132M Series B Financing >> Comment below! #mhealth #AI #healthtech #IoT #industry40
Azafaros nets €132M series B to fund late-stage development of lysosomal storage disorders drug firstwordpharma.com/story/5960104
May 13, 2025 at 9:33 AM
Azafaros nets €132M series B to fund late-stage development of lysosomal storage disorders drug firstwordpharma.com/story/5960104